President Trump has signaled—often and recently—that he believes drug approval moves too slowly. Meeting with drug manufacturers at the White House on Jan. 31, Trump promised quick yes-or-no approval decisions on new drugs (and stressed the need for lower prices and U.S.-based manufacturing).Read more
About this blog
Case Disclosed is a blog written by students, supervising attorneys, directors, alumni, and friends of the Media Freedom & Information Access Clinic.
The views expressed on this blog belong to the author(s) and do not represent the views of Yale Law School or the Media Freedom and Information Access Clinic (MFIA).